Melanoma Vaccine: Can Intismeran Reduce Recurrence?

What did the melanoma vaccine trial show?

The August 19 announcement concerned INTerpath-001, a randomized phase 3 trial involving 1,137 people with completely removed stage IIB–IV melanoma. The combination met its primary endpoint of recurrence-free survival and a secondary endpoint measuring freedom from distant metastasis. Both endpoints include death. The announcement did not disclose numerical effect sizes, and follow-up for overall survival continues. These are company-reported findings. [Merck and Moderna trial announcement](https://www.merck.com/news/merck-and-moderna-announce-phase-3-interpath-001-trial-of-intismeran-autogene-plus-keytruda-met-endpoints-of-recurrence-free-survival-rfs-and-distant-metastasis-free-survival-dmfs-in-patient/)

Earlier evidence comes from KEYNOTE-942, a randomized phase 2b study of 157 patients whose initial results appeared in The Lancet. At approximately five years of follow-up, the companies reported a 49% lower hazard of recurrence or death with the combination. That relative measure does not mean 49 additional people out of every 100 avoided recurrence. It also belongs to the earlier study and should not be presented as the phase 3 result. [Published phase 2b study](https://pubmed.ncbi.nlm.nih.gov/38246194/), [five-year follow-up](https://www.merck.com/news/moderna-and-merck-present-5-year-data-for-intismeran-autogene-in-combination-with-keytruda-pembrolizumab-in-patients-with-high-risk-stage-iii-iv-melanoma-following-complete-resection-at-the-20/)

How does a personalized mRNA cancer vaccine work?

Personalized vaccine production starts with analysis of a tumor sample. Researchers identify mutations that can produce distinctive protein targets, called neoantigens, and select targets for an individualized mRNA formulation. After vaccination, cells use those instructions to make proteins that can be presented to the immune system. The aim is to generate T cells capable of recognizing and attacking cancer cells carrying the same targets. [National Cancer Institute explanation](https://www.cancer.gov/news-events/cancer-currents-blog/2022/mrna-vaccines-to-treat-cancer)

Pembrolizumab contributes a complementary action: it blocks the PD-1 immune checkpoint, helping T cells remain active against cancer. The vaccine is intended to sharpen recognition of the tumor. This is treatment for people already diagnosed with cancer, including those receiving therapy after surgery to reduce recurrence risk. It is not a routine vaccination for healthy people. The National Cancer Institute distinguishes these therapeutic vaccines from vaccines that prevent cancer-causing infections. [NCI cancer treatment vaccines](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/cancer-treatment-vaccines)

What must patients know about safety and availability?

Fatigue, injection-site pain and chills were common in the earlier trial's five-year report. In the initial peer-reviewed analysis, grade 3 or worse treatment-related adverse events occurred in 25% of combination recipients and 18% of those receiving pembrolizumab alone. These figures describe the earlier study, not the newly announced phase 3 trial. They show why assessment must consider the whole treatment combination, even when many vaccine-associated reactions are mild or moderate. [KEYNOTE-942 safety findings](https://pubmed.ncbi.nlm.nih.gov/38246194/)

Moderna has scheduled the detailed INTerpath-001 presentation for October 24 at the European Society for Medical Oncology congress. For clinicians, important questions include the absolute difference in recurrence rates, duration of follow-up, treatment discontinuations and results across disease stages. A positive trial announcement does not establish regulatory approval or a launch date. Patients interested in investigational treatment can discuss trial eligibility with their oncology team while continuing their agreed care plan. [Moderna presentation announcement](https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/moderna-announces-late-breaking-data-to-be-presented-at-esmo-congress-1224628)